3,414 Shares in Biogen Inc. $BIIB Purchased by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 3,414 shares of the biotechnology company’s stock, valued at approximately $693,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in Biogen during the 4th quarter worth approximately $464,408,000. Boston Partners bought a new stake in shares of Biogen in the 4th quarter valued at approximately $302,815,000. Fred Alger Management LLC increased its holdings in shares of Biogen by 39,074.8% in the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after acquiring an additional 796,735 shares during the last quarter. Employees Provident Fund Board acquired a new stake in shares of Biogen during the 4th quarter valued at approximately $123,931,000. Finally, Orion Porfolio Solutions LLC raised its position in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after acquiring an additional 509,809 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on BIIB. Guggenheim lifted their price objective on shares of Biogen from $260.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Rothschild & Co Redburn increased their target price on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Oppenheimer restated an “outperform” rating and issued a $300.00 price target on shares of Biogen in a research report on Wednesday, July 29th. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. Finally, Royal Bank Of Canada decreased their price target on shares of Biogen from $242.00 to $240.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $227.07.

Biogen Trading Down 0.4%

Shares of NASDAQ BIIB opened at $209.83 on Friday. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $219.72. The company has a market cap of $31.00 billion, a price-to-earnings ratio of 37.14, a price-to-earnings-growth ratio of 6.48 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The stock’s 50 day simple moving average is $203.76 and its 200 day simple moving average is $193.10.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a return on equity of 11.18% and a net margin of 8.32%.The firm’s revenue was up 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Equities research analysts expect that Biogen Inc. will post 12.5 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.